Dr Reddy's receives two USFDA observations for New York API facility
Dr Reddy's Laboratories
announced on Saturday that the United States Food and Drug Administration (
USFDA
) has issued a Form 483 with two observations following an inspection of its API (Active Pharmaceutical Ingredients) manufacturing facility in Middleburgh, New York.
In a regulatory filing, the Hyderabad-based pharmaceutical company stated that the GMP (Good Manufacturing Practice) inspection was carried out between May 12 and May 16, 2025, news agency PTI reported.
'At the conclusion of the inspection, we received a Form 483 with two observations, which we will address within the stipulated timeline,' the company said.
According to the USFDA, a Form 483 is issued when inspectors identify conditions that may potentially violate the Food, Drug, and Cosmetic (FD&C) Act or related regulations.
The observations are shared with a firm's management to prompt corrective action.
On May 16, Dr Reddy's Laboratories Ltd closed at Rs 1,228.50, marking a decline of Rs 7.80 or 0.63% from the previous trading session.
Earlier on Friday, Dr Reddy's Laboratories had reported a 21 per cent year-on-year increase in consolidated net profit to Rs 1,587 crore for the quarter ended March 2025, driven by strong sales across key markets such as the US and India.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Avoid Emotional Trades in Volatile Markets – Master Swing with Hemant
TradeWise
Learn More
Undo
The Hyderabad-based pharmaceutical company had recorded a net profit of Rs 1,307 crore in the same quarter of the previous year. Revenue for the January–March quarter had risen to Rs 8,506 crore, compared to Rs 7,083 crore a year earlier, according to a regulatory filing.
For the full financial year 2024–25, Dr Reddy's had posted a net profit of Rs 5,724 crore, marking a modest 3 per cent growth over the Rs 5,568 crore reported in FY24.
The company's annual revenue had increased to Rs 32,553 crore from Rs 27,916 crore in the preceding fiscal.
India's Pharma sector
India's
pharmaceutical industry
, a major supplier to the United States, is likely to come under increasing pressure amid heightened regulatory scrutiny. In FY24, the US accounted for $8.7 billion of India's total pharma exports of $27.9 billion, according to the Pharmaceuticals Export Promotion Council of India.
More than 45% of the generic drugs used in the US are manufactured in India, underscoring the country's crucial role in the American healthcare system, according to an ET report.
Additionally, Indian firms supply approximately 15% of the biosimilars consumed in the US. Leading companies such as Sun Pharma, Dr Reddy's, Aurobindo Pharma, Zydus Lifesciences, and Gland Pharma generate up to half of their revenues from the US market, making them particularly sensitive to regulatory developments.
Stay informed with the latest
business
news, updates on
bank holidays
and
public holidays
.
AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
10 minutes ago
- Business Standard
Google rolls out buyout offers in US teams as AI spending takes priority
Google on Tuesday initiated a fresh round of voluntary buyout offers across multiple US-based departments, including the knowledge and information (K&I) unit, central engineering, marketing, communications, and research teams, according to a report by CNBC. The K&I division includes major departments such as Search, Advertising, and Commerce. A voluntary buyout—or voluntary exit programme (VEP)—is a financial incentive offered to employees to resign willingly, typically implemented as a cost-cutting or restructuring strategy. A Google spokesperson confirmed the initiative to CNBC, stating: 'Earlier this year, some of our teams introduced a voluntary exit program with severance for U.S.-based Googlers, and several more are now offering the program to support our important work ahead.' However, the exact number of affected employees has not been disclosed. 'You may leave if you don't feel energised': Fox memo Nick Fox, who has headed the K&I unit since an October 2023 reorganisation, addressed staff in a memo urging those who feel disconnected from the company's goals or struggling with performance expectations to consider the exit offer. 'I want to be very clear: If you're excited about your work, energised by the opportunity ahead, and performing well, I really (really!) hope you don't take this,' Fox wrote in the internal communication. 'On the other hand, this VEP offers a supportive exit path for those of you who don't feel aligned with our strategy, don't feel energised by your work, or are having difficulty meeting the expectations of your role.' The exit programme applies only to full-time US-based employees. In addition, remote workers within 50 miles of a Google office are being asked to return to the office under a hybrid schedule. Previous buyouts across teams This is not the first time Google has turned to buyouts. In January, its Platforms and Devices division—including Android, Chrome, and Pixel hardware—introduced a similar voluntary exit scheme. This was followed by the People Operations division in February, which offered mid- to senior-level staff up to 14 weeks of severance, plus one additional week per year of service. Legal and finance departments have also implemented buyout initiatives. Fox noted that he reviewed earlier programmes and received positive feedback from other teams before adopting the approach for the K&I unit. AI focus drives internal restructuring Google's increased use of voluntary exits reflects its broader strategy to reallocate resources toward artificial intelligence infrastructure. The company is also investing in internal training programmes focused on deploying practical AI tools across its products. Earlier this year, some employees welcomed the buyout option over abrupt layoffs. However, the buyout offers often come with return-to-office conditions. According to an April report by CNBC, some remote employees were told to resume in-office work to retain their roles and avoid further job uncertainty.
Time of India
11 minutes ago
- Time of India
Mansion House brand's global ownership goes to Allied Blenders
Allied Blenders and Distillers Ltd (ABD) has acquired global ownership of the 'Mansion House' and 'Savoy Club' liquor brands by fully acquiring Singapore-based UTO Asia Pte. Ltd. In a meeting held on June 10, 2025, ABD's board of directors approved the acquisition of 100% equity share capital of UTO Asia, the spirits co announced on Wednesday. The total consideration for the deal was €1.225 million (excluding stamp duty and levies), and the transaction has been concluded with immediate effect. With this acquisition, UTO Asia becomes a wholly owned subsidiary of ABD. The company holds legal and beneficial rights to the Mansion House and Savoy Club brands globally — excluding certain Southeast Asian markets : Singapore, Malaysia, Indonesia, Philippines, Thailand, Cambodia, Vietnam, Laos, China, and Myanmar. ABD said the deal aligns with its strategic expansion goals and enables it to strengthen its brand positioning across international markets. 'The acquisition of UTO Asia and the associated ownership of worldwide right, title and interest in the Mansion House and Savoy Club brands… allows it to gain full control over the brands on a global scale, while specifically addressing regional interests in key markets,' the company said in a statement. The acquisition, ABD added, is expected to help enhance brand presence and drive growth in the global liquor segment.
Time of India
12 minutes ago
- Time of India
United Breweries receives Rs 18.60 cr GST order
Liquor major United Breweries on Wednesday said that the company has received orders and demand notices from the Kerala State Goods & Services Tax Department , Palakkad. The demand was raised alleging non-payment of turnover tax on the sale of beer, the company said in an exchange filing. The total tax demand stands at Rs 18.60 crore plus applicable interest and pertains to FY 2022-23 and 2023-24. United Breweries shares were trading at Rs 2059.85 apiece on the BSE, down 0.26 per cent in the final session of Wednesday. The maker of Kingfisher beer said that it has made adequate provision in the financials for the above demand, hence it will not have any material impact. "The Company is exploring appropriate legal remedies against the said orders," United Breweries said.
